Despite conventional therapies, such as chemotherapy and radiation therapy, the treatment of relapsed lymphoma remains challenging, with the disease persisting in many patients. The goal of this study is to evaluate the safety and potential anti-lymphoma effectiveness of CPI-0610 in patients whose lymphoma has persisted or returned despite treatment with standard therapy.
CPI-0610 is an investigational drug designed to inhibit cancer growth by blocking a group of proteins called BET proteins. BET are known to regulate the cellular levels of different proteins that promote cancer cell growth and survival. CPI-0610 is taken orally (by mouth).